Innova Captab Ltd

- No specific mention of new fundraising through debt or equity in the current call. - The company has repaid all existing debt excluding the term loan for the Jammu project. - The Jammu project is funded partly by a Rs. 235 crore project loan at 6% interest subvention. - IPO proceeds of Rs. 293 crores are being deployed as planned over two years; about Rs. 62 crores planned for FY25. - No indication of fresh equity or debt raising beyond the existing Jammu project loan and IPO proceeds utilization. - Capex plans include another Rs. 100 crore investment in the Jammu facility during the year. - Overall, the company appears focused on utilizing current resources and existing loans rather than new fundraising.

- Ongoing capital work in progress is primarily for the Jammu project, with around Rs. 330 crore invested so far. - Total anticipated project cost for Jammu facility is approximately Rs. 450 crore, with an expected additional Rs. 100 crore investment in coming quarters. - Commercial production at Jammu is planned to start in Q2 FY25. - Normal maintenance CAPEX for existing operations is estimated around Rs. 5-7 crores per annum. - Future investments aim to enhance capacity, including three more blocks at Jammu and expansion of Cephalosporin block. - The company expects to utilize IPO proceeds as planned and has repaid all existing debt except the project loan for Jammu. - Jammu facility benefits from GST and interest subvention incentives expected to improve margin profile.

- The company expects a strong growth in CDMO business, targeting 20%+ CAGR in the coming year, driven by new capacity from Jammu facility and increased utilization of existing facilities. - Volume growth in CDMO is projected at 10%+ annually; revenue growth depends on price stability or increase. - With the Jammu facility coming online, acute segment sales are expected to increase, boosting overall revenue. - Gross margins expected to stabilize around 25%-26%, with improved margins from Jammu due to GST benefits. - EBITDA growth is linked to volume growth rather than top-line revenue, with a 10% increase in standalone EBITDA reported. - Export business and branded generics are also focused growth areas alongside CDMO. - New inquiries and customer onboarding for Jammu facility are in advanced stages, expected to convert into revenue within 4-5 months post commercial production start.

- Innova Captab is optimistic about 20%+ CAGR growth in the near term driven by: - Expansion and commissioning of the new Jammu facility with state-of-the-art automation. - Volume growth in CDMO business expected at 10%+ despite price erosion. - EBITDA growth supported by volume increases and GST benefits from Jammu facility. - FY24 EBITDA grew by 35.9% to Rs. 166.9 crores; PAT grew 38.9% to Rs. 94.3 crores YoY. - EBITDA margin expected to remain around 25% ± 2-3% with potential improvement from GST benefits. - The company expects revenue from Jammu facility to exceed Rs. 1,000 crore over 3-4 years. - Sustainable gross margins anticipated around 25%-26%, aided by higher-margin branded and Sharon businesses. - Realignment and integration of acquired Sharon entities expected to support profitability improvement. - Management aims to maintain operational efficiencies, cash generation, and steady maintenance CAPEX (Rs. 5-7 crores per annum).

- The company is in advanced discussions for commercial production at its Jammu facility, expecting revenue ramp-up 4-5 months after starting. - Current visibility on new inquiries and orders is positive, especially with existing customers and new product SKUs. - The existing facilities at Baddi have spare capacity, particularly in the General block (40%-45% utilization), while Cephalosporin block is heavily utilized (~70%). - The company is aiming to increase wallet share with existing customers and onboard new customers. - Jammu facility investments (~Rs. 100-120 crores) are expected to add capacity and contribute to growth. - With capacity expansions and new facilities, a 20%+ CAGR in the CDMO category is targeted. - The order book appears strong based on customer engagement and capacity ramp-up plans, although exact orderbook numbers are not provided.